Literature DB >> 231062

Effects of somatostatin on insulin and glucagon in patients with insulinoma.

F Fallucca, C Mirabella, G Tamburrano, S Gambardella, G Aufieri, F Barbetti, D Andreani.   

Abstract

Effects of somatostatin on fasting and arginine-or tolbutamide-stimulated insulin release were studied in four patients with insulinoma. Somatostatin (bolus or bolus + infusion) reduced fasting insulin values in all patients; insulin response to tolbutamide was partially reduced in two patients; somatostatin bolus impaired the insulin response to arginine. Fasting glucagon levels and glucagon response to arginine were also reduced by somatostatin. These results indicate the potential usefulness of somatostatin in the diagnosis of insulinoma even if its effect on insulin is only partial.

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 231062     DOI： 10.1007/BF03350412

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN： 0391-4097            Impact factor:   4.256


  15 in total

1.  Immunoassay of insulin with insulin-antibody precipitate.

Authors:  C N HALES; P J RANDLE
Journal:  Biochem J       Date:  1963-07       Impact factor: 3.857

2.  Failure of somatostatin to inhibit tolbutamide-induced insulin secretion in patients with insulinomas: a possible diagnostic tool.

Authors:  M Lorenzi; J E Gerich; J H Karam; P H Forsham
Journal:  J Clin Endocrinol Metab       Date:  1975-06       Impact factor: 5.958

3.  Specific inhibition by somatostatin of growth hormone release after hypoglycaemia in normal man.

Authors:  G Copinschi; E Virasoro; L Vanhaelst; R Leclercq; J Golstein; M L'Hermite
Journal:  Clin Endocrinol (Oxf)       Date:  1974-10       Impact factor: 3.478

4.  Effect of somatostatin in patients with acromegaly: suppression of growth hormone, prolactin, insulin and glucose levels.

Authors:  S S Yen; T M Siler; G W DeVane
Journal:  N Engl J Med       Date:  1974-04-25       Impact factor: 91.245

5.  Somatostatin: hypothalamic inhibitor of the endocrine pancreas.

Authors:  D J Koerker; W Ruch; E Chideckel; J Palmer; C J Goodner; J Ensinck; C C Gale
Journal:  Science       Date:  1974-04-26       Impact factor: 47.728

6.  Direct inhibition of insulin secretion by synthetic somatostatin.

Authors:  D L Curry; L L Bennett; C H Li
Journal:  Biochem Biophys Res Commun       Date:  1974-06-04       Impact factor: 3.575

7.  Action of growth-hormone-release inhibitory hormone in healthy men and in acromegaly.

Authors:  R Hall; G M Besser; A V Schally; D H Coy; D Evered; D J Goldie; A J Kastin; A S McNeilly; C H Mortimer; C Phenekos; W M Tunbridge; D Weightman
Journal:  Lancet       Date:  1973-09-15       Impact factor: 79.321

8.  Inhibition of insulin secretion by somatostatin.

Authors:  K G Alberti; N J Christensen; S E Christensen; A P Hansen; J Iversen; K Lundbaek; K Seyer-Hansen; H Orskov
Journal:  Lancet       Date:  1973-12-08       Impact factor: 79.321

9.  Inhibition of growth hormone release in humans by somatostatin.

Authors:  T M Siler; G VandenBerg; S S Yen; P Brazeau; W Vale; R Guillemin
Journal:  J Clin Endocrinol Metab       Date:  1973-10       Impact factor: 5.958

10.  Response of islet cell tumors to enterohormones.

Authors:  F Fallucca; S Tamburrano; S Gambardella; G Menzinger
Journal:  Horm Metab Res       Date:  1976       Impact factor: 2.936
View more
  3 in total

1.  Effect of somatostatin on gastrin, insulin and glucagon secretion in two patients with Zollinger-Ellison syndrome.

Authors:  F Fallucca; G Delle Fave; L Giangrande; P Del Balzo; L De Magistris; R Carratù
Journal:  J Endocrinol Invest       Date:  1981 Oct-Dec       Impact factor: 4.256

2.  Gastroenteropancreatic endocrine tumors.

Authors:  C Weil
Journal:  Klin Wochenschr       Date:  1985-05-15

Review 3.  Somatostatin analogues for the treatment of hyperinsulinaemic hypoglycaemia.

Authors:  Basma Haris; Saras Saraswathi; Khalid Hussain
Journal:  Ther Adv Endocrinol Metab       Date:  2020-12-02       Impact factor: 3.565
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.